Skip to main content
. 2024 Jul 31;11(3):13–22. doi: 10.15586/jkcvhl.v11i3.319

Table 2:

Distribution of metastatic involvement in patients with mRCC with or without thromboembolic complications.

Site of metastatic involvement n (%) TE (N=42) No TE (N=328) p-value
Lymph node 14 (33) 155 (47) 0.09
Lung 27 (64) 221 (67) 0.69
Brain 6 (14) 28 (8) 0.23
Liver 6 (14) 59 (18) 0.55
Bone 14 (33) 100 (30) 0.71
Adrenal 3 (7) 48 (15) 0.18
Pancreatic 5 (12) 19 (6) 0.13
Other 6 (14) 93 (28) 0.05